COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,725 Articles (22,913 medRxiv, 8,812 bioRxiv)

Most recent first Previous |  Page 1494: Articles 14931-14940  | Next

Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study
Misra, P., WHO Unity Seroprevalence study team of AIIMS
10.1101/2021.06.15.21258880 — Posted: 2021-06-16
Relative perceived importance of different settings for SARS-CoV2 acquisition in England and Wales: Analysis of the Virus Watch Community Cohort
Beale, S., Byrne, T. E., Fragaszy, E. B., Kovar, J., Nguyen, V. G., Aryee, A., Fong, W. L. E., Geismar, C. R., Patel, P., Shrotri, M., Patni, N., Braithwaite, I., Navaratnam, A. M. D., Aldridge, R. W., Hayward, A. C.
10.1101/2021.06.11.21258730 — Posted: 2021-06-16
A Novel and Expanding SARS-CoV-2 Variant, B.1.1.318, dominates infections in Mauritius
Tegally, H., Ramuth, M., Amoaka, D., Scheepers, C., Wilkinson, E., Giovanetti, M., Lessells, R. J., Giandhari, J., Ismail, A., Martin, D., San, E. J., Crawford, M., Daniels, R. S., Harvey, R., Bahadoor, S., Sonoo, J., Timol, M., Veerapa-Mangroo, L., von Gottberg, A., Bhiman, J., de Oliveira, T., Manraj, S.
10.1101/2021.06.16.21259017 — Posted: 2021-06-16
Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety and chronic fatigue syndrome-like symptoms due to COVID-19: a nomothetic network approach.
Al-Jassas, H., Al-Hakeim, H. K., Maes, M.
10.1101/2021.06.12.21258815 — Posted: 2021-06-16
Social Contact Patterns and Implications for Infectious Disease Transmission: A Systematic Review and Meta-Analysis of Contact Surveys
Mousa, A., Winskill, P., Watson, O. J., Ratmann, O., Monod, M., Ajelli, M., Diallo, A., Dodd, P. J., Grijalva, C. G., Kiti, M. C., Krishnan, A., Kumar, R., Kumar, S., Kwok, K. O., Lanata, C. F., le Polain de Waroux, O., Leung, K., Mahikul, W., Melegaro, A., Morrow, C. D., Mossong, J., Neal, E. F., Nokes, D. J., Pan-ngum, W., Potter, G. E., Russell, F. M., Saha, S., Sugimoto, J. D., Wei, W. I., Wood, R. R., Wu, J., Zhang, J., Walker, P., Whittaker, C.
10.1101/2021.06.10.21258720 — Posted: 2021-06-16
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby, P. W., Mafham, M., Peto, L., Campbell, M., Pessoa-Amorim, G., Spata, E., Staplin, N., Emberson, J. R., Prudon, B., Hine, P., Brown, T., Green, C. A., Sarkar, R., Desai, P., Yates, B., Bewick, T., Tiberi, S., Felton, T., Baillie, J. K., Buch, M. H., Chappell, L. C., Day, J. N., Faust, S. N., Jaki, T., Jeffery, K., Juszczak, E., Lim, W. S., Montgomery, A., Mumford, A., Rowan, K., Thwaites, G., Weinreich, D. M., Haynes, R., Landray, M. J.
10.1101/2021.06.15.21258542 — Posted: 2021-06-16 Discussion: Onsite
High efficacy of therapeutic equine hyperimmune antibodies against SARS CoV-2 variants of concern
Moreira-Soto, A., Arguedas, M., Brenes, H., Bujan, W., Corrales-Aguilar, E., Diaz, C., Echeverri, A., Flores-Diaz, M., Gomez, A., Hernandez, A., Herrera, M., Leon, G., Macaya, R., Khüne, A., Molina-Mora, J. A., Mora, J., Sanabria, A., Sanchez, A., Sanchez, L., Segura, A., Segura, E., Solano, D., Soto, C., Stynoski, J. L., Vargas, M., Villalta, M., Reusken, C., Drosten, C., Gutierrez, J. M., Alape-Giron, A., Drexler, J. F.
10.1101/2021.06.12.448080 — Posted: 2021-06-16
Reconstruction of a large-scale outbreak of SARS-CoV-2 infection in Iceland informs vaccination strategies
Eldjarn Hjorleifsson, K., Rognvaldsson, S., Jonsson, H., Agustsdottir, A. B., Andresdottir, M., Birgisdottir, K., Eiriksson, O., Eythorsson, E. S., Fridriksdottir, R., Georgsson, G., Gudmundsson, K. R., Gylfason, A., Haraldsdottir, G., Jensson, B. O., Jonasdottir, A., Jonasdottir, A., Josefsdottir, K. S., Kristinsdottir, N., Kristjansdottir, B., Kristjansson, T., Magnusdottir, D. N., Palsson, R., le Roux, L., Sigurbergsdottir, G. M., Sigurdsson, A., Sigurdsson, M. I., Sveinbjornsson, G., Thorarensen, E. A., Thorbjornsson, B., Thordardottir, M., Helgason, A., Holm, H., Jonsdottir, I., Jonsson, F., Magnusson, O. T., Masson, G., Norddahl, G. L., Saemundsdottir, J., Sulem, P., Thorsteinsdottir, U., Gudbjartsson, D. F., Melsted, P., Stefansson, K.
10.1101/2021.06.11.21258741 — Posted: 2021-06-16
Role of Hemogram-Derived Ratios and Systemic-Immune Inflammation Index in Prediction of COVID-19 Progression in Egyptian Patients
Taha, S. I., Samaan, S. F., Baioumy, S. A., Shata, A. K., Youssef, M. K.
10.1101/2021.06.10.21258715 — Posted: 2021-06-16
Baseline Characteristics and Outcomes of 180 Egyptian COVID-19 Patients Admitted to Quarantine Hospitals of Ain Shams University: A Retrospective Comparative Study
Taha, S. I., Samaan, S. F., Shata, A. K., Baioumy, S. A., Abdalgeleel, S. A., Youssef, M. K.
10.1101/2021.06.11.21258743 — Posted: 2021-06-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).